From GlobeNewswire: 2024-04-02 07:30:00

AIM ImmunoTech Inc. reported positive data for 2023 and Q1 2024, aiming to create stockholder value. Recent highlights include positive findings for Ampligen in pancreatic cancer treatment and a key U.S. patent issuance for Ampligen with an anti-PD-L1 antibody. The Company will host a conference call and webcast on April 2, 2024, to discuss financial results and upcoming milestones. Financial highlights show cash of $13.1 million as of December 31, 2023, with research and development expenses of $10.9 million, and general and administrative expenses of $21.1 million for 2023. AIM ImmunoTech Inc. focuses on developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19, with their lead product Ampligen® (rintatolimod), a TLR3 agonist immuno-modulator. The Company will host a conference call and webcast on April 2, 2024, at 8:30 AM ET for interested participants and investors.

AIM ImmunoTech Inc. saw promising data in 2023 and Q1 2024, highlighting positive results for Ampligen in pancreatic cancer and securing a key U.S. patent issuance. The Company will host a conference call and webcast on April 2, 2024, to discuss financial results and upcoming pipeline milestones. Financial highlights include cash of $13.1 million as of December 31, 2023, with research and development expenses of $10.9 million and general and administrative expenses of $21.1 million for 2023. AIM ImmunoTech Inc. focuses on developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19, with their lead product Ampligen® (rintatolimod), a TLR3 agonist immuno-modulator. Join the conference call and webcast today at 8:30 AM ET to learn more about the Company’s progress and future plans.



Read more at GlobeNewswire:: AIM ImmunoTech Reports Fourth Quarter and Full Year 2023